Competing interests
ONCOLOGY
Peter Schmid reports receiving consultancy fees/honorarium from AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, Roche, Eisai, and Celgene; receiving institutional funding from Astellas, AstraZeneca, Genentech, Novartis, OncoGenex, Roche, and Medivation; and having an immediate family member employed by Roche. Javier Cortes reports receiving fees for consulting/advisor roles with Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics; receiving honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, Daiichi Sankyo; holding stock, patents and intellectual property with MedSIR, Nektar Pharmaceuticals; and travel, accommodation, expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, AstraZeneca. Ana Joaquim has received fees for consulting/advisor roles, in the last 3 years, from Daiichi Sankyo, Eisai, Gilead, Glaxo Smith Kline, Lilly, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Vifor Pharma and Zuellig Pharma. Julie Lemieux has served in a consultancy or advisory role and received honorarium from Novartis, Eli Lilly, Gilead, Pfizer, and AstraZeneca; and has received research funding from Celgene, Genentech, GlaxoSmithKline, Roche, Millennium, Novartis, Merck Gilead, Abbvie, Acerta, Bayer, Pfizer, BMS, Esai, Sanofi, Janssen, Ozmosys, Sierra AstraZeneca, and Takeda. José Ángel García-Sáenz reported grants from SeaGen, Gilead, Eli Lilly and Company, AstraZeneca, and Daiichi Sankyo; and personal fees from Novartis, Eisai, and Merck Sharp & Dohme. Lowell Hart serves on the advisory boards and consults for Novartis, G1 Therapeutics, Seattle Genetics, AstraZeneca, and Nanostring. Tsvetan Biyukov, Navid Baktash are employees of Boehringer Ingelheim. Dan Massey is an employee of Elderbrook Solutions contracted by Boehringer Ingelheim. Hope Rugo reports receiving honoraria from Puma Biotechnology, Mylan, Samsung Bioepis, Chugai Pharma, Blueprint Medicines; receiving fees for a consulting or advisory role with Napo Pharmaceuticals; and institutional research funding from OBI Pharma, Pfizer, Novartis, Lilly, Genentech, Merck, Odonate Therapeutics, Daiichi Sankyo, Sermonix Pharmaceuticals, AstraZeneca, Gilead Sciences, Ayala Pharmaceuticals, Astellas Pharma, Seattle Genetics, MacroGenics, Boehringer Ingelheim, Polyphor. All other authors report no conflicts of interest.